TARS
NASDAQTarsus Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks65-97%
2025-10-262026-04-19
Mix4690d
- Insider26(57%)
- SEC Filings12(26%)
- Other5(11%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- PRTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs. Calliope is a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability and pharmacokinetics of orally administered TP-05 in approximately 700 healthy adults at r
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- INSIDERSEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- PRTP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusIRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China. The approval was obtained by Grand Pharmaceutical Group Limited ("Grand Pharma"), Tarsus' exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region, which includes the People's Republic of China, Hong Kong, Macau and Taiwan. "TP-03 is once
- INSIDERSEC Form 4 filed by Whitfield Dianne C.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Wahl Bryan4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Mottiwala Aziz4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Lin Elizabeth Yeu4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Farrow Jeffrey S4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Azamian Bobak R.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- INSIDERSEC Form 4 filed by Link William J Phd4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Human Resources Officer Whitfield Dianne C. converted options into 23,909 shares, increasing direct ownership by 102% to 47,302 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERGeneral Counsel Wahl Bryan converted options into 24,236 shares, increasing direct ownership by 46% to 76,399 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Operating Officer Neervannan Seshadri converted options into 26,287 shares, increasing direct ownership by 37% to 97,104 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Commercial Officer Mottiwala Aziz converted options into 26,482 shares, increasing direct ownership by 55% to 74,536 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDEROfficer Farrow Jeffrey S converted options into 13,042 shares, increasing direct ownership by 36% to 49,746 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERPresident/CEO and Board Chair Azamian Bobak R. converted options into 66,274 shares, increasing direct ownership by 3,787% to 68,024 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Medical Officer Lin Elizabeth Yeu converted options into 2,511 shares, increasing direct ownership by 11% to 24,452 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)